The DOI matches its Crossref record; 47 of the 51 references it cites were found in a registry or an index.
Intranasal Oxytocin Blocks Alcohol Withdrawal in Human Subjects
Open accessAbstract
Background: The neuropeptide, oxytocin (OT), has been reported to block tolerance formation to alcohol and decrease withdrawal symptoms in alcohol‐dependent rodents. Numerous recent studies in human subjects indicate that OT administered by the intranasal route penetrates into and exerts effects within the brain. Methods: In a randomized, double‐blind clinical trial, intranasal OT (24 IU/dose, N = 7) or placebo (N = 4) was given twice daily for 3 days in alcohol‐dependent subjects admitted to a research unit for medical detoxification using Clinical Institute Withdrawal Assessment for A lcohol (CIWA) score‐driven PRN administration of lorazepam. Subjects rated themselves on the Alcohol Withdrawal Symptom Checklist (AWSC) each time CIWA scores were obtained. Subjects also completed the Penn Alcohol Craving Scale, an Alcohol Craving Visual Analog Scale (ACVAS) and the Profile of Mood States (POMS) on inpatient days 2 and 3. Results: All subjects had drunk heavily each day for at least 2 weeks prior to study and had previously experienced withdrawal upon stopping/decreasing alcohol consumption. OT was superior to placebo in reducing alcohol withdrawal as evidenced by: less total lorazepam required to complete detoxification (3.4 mg [4.7, SD] vs. 16.5 [4.4], p = 0.0015), lower mean CIWA scores on admission day 1 (4.3 [2.3] vs. 11.8 [0.4], p < 0.0001) and day 2 (3.4 [2.2] vs. 11.1 [3.6], p < 0.002), lower AWSC scores on days 1 and 2 (p < 0.02; p = 0.07), and lower ACVAS ratings (p = 0.01) and lower POMS Tension/Anxiety subscale scores on day 2 (p < 0.01). Conclusions: This is the first demonstration that OT treatment may block alcohol withdrawal in human subjects. Our results are consistent with previous findings in rodents that OT inhibits neuroadaptation to and withdrawal from alcohol. OT could have advantages over benzodiazepines in managing alcohol withdrawal because it may reverse rather than maintain sedative‐hypnotic tolerance. It will be important to test whether OT treatment is effective in reducing drinking in alcohol‐dependent outpatients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A small study showed that intranasal oxytocin blocked alcohol withdrawal in humans, based on such measures as the Alcohol Withdrawal Symptom Checklist of the Clinical Institute Withdrawal Assessment for Alcohol, and reduced the amount of benzodiazepines that were required for treatment (Pedersen et al., 2013).”
From Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development (2021) · cites this paper as Pedersen et al., 2013
In the citing paper
“In two recent studies, OXT IN was found to suppress stress-induced craving in cannabis-dependent individuals (134) and to block alcohol withdrawal (135).”
From Dissecting the Role of Oxytocin in the Formation and Loss of Social Relationships (2016) · cites this paper as [135]
In the citing paper
“Safety and feasibility of daily dosing has been demonstrated in other human OT studies including those with alcohol-dependent patients (Pedersen et al., 2013), patients with schizophrenia (Pedersen et al., 2011) and individuals with trauma exposure (van Zuiden et al., 2016).”
From Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: a randomized, placebo-controlled pilot trial (2018) · cites this paper as Pedersen et al., 2013
In the citing paper
“Others have found that intranasal oxytocin produces significantly less craving and anxiety to a social stress task than placebo in marijuana-dependent subjects (Carson et al., 2013; McRae-Clark et al., 2013; Pedersen et al., 2013).”
From Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence (2015) · cites this paper as Pedersen et al., 2013
In the citing paper
“For example, compared with placebo, intranasal oxytocin produced significantly lower symptoms of alcohol withdrawal and anxiety in alcohol-dependent subjects (Pedersen et al., 2013).”
From Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence (2015) · cites this paper as Pedersen et al., 2013
In the citing paper
“The neuropeptide oxytocin appears to mitigate the effects of stress in individuals with SUDs.”
From Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence (2015) · cites this paper as Pedersen et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
(1998) · PubMed · Cited by 10,216
Oxytocin increases trust in humans
Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089
Heinrichs, M., Baumgartner, T., Kirschbaum, C., & Ehlert, U. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00465-7 · Cited by 2,091
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Oxytocin improves “mind-reading” in humans
Domes, G., Heinrichs, M., Michel, A., Berger, C., & Herpertz, S. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.015 · Cited by 1,298
Oxytocin shapes the neural circuitry of trust and trust adaptation in humans
Baumgartner, T., Heinrichs, M., Vonlanthen, A., Fischbacher, U., & Fehr, E. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.009 · Cited by 1,258
Research works printed but not linked: 5
- Knapp DJ, 2010, Inhibitory effects of oxytocin on anxiety‐like behavior and alcohol consumption in P‐rats subjected to repeated cycles of voluntary ethanol consumption and stress, Alcohol Clin Exp Res, 34, 145A
- 10.1001/jama.1997.03550020076042 · DOI · Paper page
- McNair DM, 1971, EDITS Manual for the Profile of Mood States
- Vadlamudi S, 2004, Neuroadaptation to alcohol and morphine is altered in oxytocin knockout mice
- 10.1210/endo.138.7.5255 · DOI · Paper page
Cited by
Sorted by citations
The oxytocin receptor: from intracellular signaling to behavior
Jurek, B., & Neumann, I. D. (2018) · Physiological Reviews · doi:10.1152/physrev.00031.2017 · Cited by 999
Uvnäs-Moberg, K., Handlin, L., & Petersson, M. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2014.01529 · Cited by 351
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337
Substance use during pregnancy
Forray, A. (2016) · F1000Research · doi:10.12688/f1000research.7645.1 · Cited by 322
Immunohistochemical localization of oxytocin receptors in human brain
Boccia, M. L., Petrusz, P., Suzuki, K., Marson, L., & Pedersen, C. A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.048 · Cited by 276
Self-citationInfluence of stress associated with chronic alcohol exposure on drinking
Becker, H. C. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.028 · Cited by 191
MacDonald, K., & Feifel, D. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00035 · Cited by 181
Nose-to-brain peptide delivery – The potential of nanotechnology
Samaridou, E., & Alonso, M. J. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.11.001 · Cited by 183
Pathophysiology of the Effects of Alcohol Abuse on the Endocrine System
Rachdaoui, N. (2017) · Alcohol research · doi:10.35946/arcr.v38.2.08 · Cited by 180
Peris, J., MacFadyen, K. A., Smith, J. A., de Kloet, A. D., Wang, L. A., & Krause, E. G. (2016) · The Journal of Comparative Neurology · doi:10.1002/cne.24116 · Cited by 158
Economic demand predicts addiction-like behavior and therapeutic efficacy of oxytocin in the rat
Bentzley, B. S., Jhou, T. C., & Aston‐Jones, G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406324111 · Cited by 151
Buisman‐Pijlman, F. T. A., Sumracki, N. M., Gordon, J. J., Hull, P. R., Carter, C. S., & Tops, M. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.09.005 · Cited by 147
Oxytocin׳s role in anxiety: A critical appraisal
MacDonald, K., & Feifel, D. (2014) · Brain Research · doi:10.1016/j.brainres.2014.01.025 · Cited by 139
Dissecting the Role of Oxytocin in the Formation and Loss of Social Relationships
Hurlemann, R., & Scheele, D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.05.013 · Cited by 136
Concurrent Treatment of Substance Use and PTSD
Flanagan, J. C., Korte, K. J., Killeen, T. K., & Back, S. E. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0709-y · Cited by 136
Flanagan, J. C., Sippel, L. M., Wahlquist, A., Moran-Santa Maria, M. M., & Back, S. E. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.12.014 · Cited by 117
The Role of the Central Amygdala in Alcohol Dependence
Roberto, M., Kirson, D., & Khom, S. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039339 · Cited by 112
Oxytocin reduces alcohol cue-reactivity in alcohol-dependent rats and humans
Hansson, A. C., Koopmann, A., Uhrig, S., Bühler, S., Domi, E., Kiessling, E., Ciccocioppo, R., Froemke, R. C., Grinevich, V., Kiefer, F., et al. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.257 · Cited by 109
Oxytocin for the treatment of drug and alcohol use disorders
Lee, M. R., & Weerts, E. M. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000258 · Cited by 105
Tunstall, B. J., Kirson, D., Zallar, L. J., McConnell, S. A., Vendruscolo, J. C. M., Ho, C. P., Oleata, C. S., Khom, S., Manning, M., Lee, M. R., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.2006421 · Cited by 104
Oxytocin inhibits ethanol consumption and ethanol‐induced dopamine release in the nucleus accumbens
Peters, S., Bowen, M. T., Bohrer, K., McGregor, I. S., & Neumann, I. D. (2016) · Addiction Biology · doi:10.1111/adb.12362 · Cited by 101
Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date
Lee, M. R., Rohn, M. C. H., Tanda, G., & Leggio, L. (2016) · CNS Drugs · doi:10.1007/s40263-016-0313-z · Cited by 102
Oxytocin Acts in Nucleus Accumbens to Attenuate Methamphetamine Seeking and Demand
Cox, B. M., Bentzley, B. S., Regen-Tuero, H. C., See, R. E., Reichel, C. M., & Aston‐Jones, G. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.11.011 · Cited by 98
Medications for alcohol use disorders: An overview
Akbar, M. D., Egli, M., Cho, Y., Song, B., & Noronha, A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.007 · Cited by 101
Evidence for Intranasal Oxytocin Delivery to the brain: Recent Advances and Future Perspectives
Quintana, D. S., Smerud, K. T., Andreassen, O. A., & Djupesland, P. G. (2018) · Therapeutic Delivery · doi:10.4155/tde-2018-0002 · Cited by 98
Oxytocin reduces ethanol self-administration in mice
King, C. E., Griffin, W. C., Luderman, L. N., Kates, M. M., McGinty, J. F., & Becker, H. C. (2017) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13359 · Cited by 89
Mitchell, J. M., Arcuni, P. A., Weinstein, D., & Woolley, J. D. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000213 · Cited by 82
Early adverse experience and substance addiction: Dopamine, oxytocin, and glucocorticoid pathways
Kim, S., Kwok, S., Mayes, L. C., Potenza, M. N., Rutherford, H. J. V., & Strathearn, L. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13140 · Cited by 85
Rebalancing the Addicted Brain: Oxytocin Interference with the Neural Substrates of Addiction
Bowen, M. T., & Neumann, I. D. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.10.003 · Cited by 88
Peripheral oxytocin administration reduces ethanol consumption in rats
MacFadyen, K., Loveless, R., DeLucca, B., Wardley, K., Deogan, S., Thomas, C., & Peris, J. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.10.014 · Cited by 76
Bowen, M. T., Peters, S. T., Absalom, N. L., Chebib, M., Neumann, I. D., & McGregor, I. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416900112 · Cited by 75
Oxytocin and Rodent Models of Addiction
Leong, K.-C., Cox, S. S., King, C. E., Becker, H. C., & Reichel, C. M. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.07.007 · Cited by 72
The role of oxytocin in alcohol and drug abuse
King, C. E., Gano, A., & Becker, H. C. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146761 · Cited by 69
Horta, M., Kaylor, K., Feifel, D., & Ebner, N. C. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.10.012 · Cited by 63
Oxytocin enhances cognitive control of food craving in women
Striepens, N., Schröter, F., Stoffel‐Wagner, B., Maier, W., Hurlemann, R., & Scheele, D. (2016) · Human Brain Mapping · doi:10.1002/hbm.23308 · Cited by 63
Yardley, M. M., & Ray, L. A. (2016) · Addiction Biology · doi:10.1111/adb.12349 · Cited by 62
Zhou, L., Sun, W., Young, A. B., Lee, K., McGinty, J. F., & See, R. E. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu009 · Cited by 57
Flanagan, J. C., Baker, N. L., McRae-Clark, A. L., Brady, K. T., & Moran-Santa Maria, M. M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.07.064 · Cited by 56
Oxytocin and opioid addiction revisited: old drug, new applications
Zanos, P., Georgiou, P., Weber, C. D., Robinson, F., Kouimtsidis, C., Niforooshan, R., & Bailey, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13757 · Cited by 54
Drug addiction: An affective-cognitive disorder in need of a cure
Fattore, L., & Diana, M. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.04.006 · Cited by 58
Oxytocin, Tolerance, and the Dark Side of Addiction
Pedersen, C. A. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.08.003 · Cited by 58
Self-citationOxytocin attenuates stress-induced reinstatement of alcohol seeking behavior in male and female mice
King, C. E., & Becker, H. C. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05233-z · Cited by 53
Everett, N. A., Turner, A. J., Costa, P. A., Baracz, S. J., & Cornish, J. L. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0719-7 · Cited by 52
Complexity of oxytocin׳s effects in a chronic cocaine dependent population
Lee, M. R., Glassman, M., King‐Casas, B., Kelly, D. L., Stein, E. A., Schroeder, J. R., & Salmeron, B. J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.06.005 · Cited by 52
Baracz, S. J., Everett, N. A., & Cornish, J. L. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.08.014 · Cited by 57
Gil, M., Bhatt, R., Picotte, K. B., & Hull, E. M. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.02.002 · Cited by 52
Regionally Specific Effects of Oxytocin on Reinstatement of Cocaine Seeking in Male and Female Rats
Weber, R. A., Logan, C. N., Leong, K.-C., Peris, J., Knackstedt, L. A., & Reichel, C. M. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy025 · Cited by 48
Stauffer, C. S., Musinipally, V., Suen, A. O., Lynch, K. L., Shapiro, B. J., & Woolley, J. D. (2016) · Addiction Research & Theory · doi:10.3109/16066359.2016.1173682 · Cited by 47
Emerging pharmacotherapies for alcohol use disorder
Mason, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.032 · Cited by 47
Oxytocin reduces alcohol consumption in prairie voles
Stevenson, J. R., Wenner, S. M., Freestone, D. M., Romaine, C. C., Parian, M. C., Christian, S. M., Bohidar, A. E., Ndem‐Galbert, J. R., Vogel, I., & O'Kane, C. M. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.07.021 · Cited by 47
Bernheim, A. P., Leong, K.-C., Berini, C., & Reichel, C. M. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.08.012 · Cited by 47
Schindler, E. A. D., Wallace, R. M., Sloshower, J., & D’Souza, D. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00177 · Cited by 51
The neurocircuitry involved in oxytocin modulation of methamphetamine addiction
Baracz, S. J., & Cornish, J. L. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.08.001 · Cited by 46
Intranasal gene delivery for treating Parkinson’s disease: overcoming the blood–brain barrier
Aly, A. E.-E., & Waszczak, B. L. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1069815 · Cited by 46
Woolley, J. D., Arcuni, P. A., Stauffer, C. S., Fulford, D., Carson, D. S., Batki, S., & Vinogradov, S. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4308-8 · Cited by 47
Hofmann, S. G., Fang, A., & Brager, D. N. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.05.039 · Cited by 44
RetractedFlanagan, J. C., Hand, A., Jarnecke, A. M., Maria, M. M. M., Brady, K. T., & Joseph, J. E. (2018) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000197 · Cited by 47
Morley, K. C., Perry, C. J., Watt, J., Hurzeler, T. P., Leggio, L., Lawrence, A. J., & Haber, P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1892641 · Cited by 44
Johnston, J., Lintzeris, N., Allsop, D. J., Suraev, A. S., Booth, J., Carson, D. S., Helliwell, D., WINSTOCK, A. R., & McGregor, I. S. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3611-5 · Cited by 43
Opioid addiction: who are your real friends?
Eitan, S., Emery, M. A., Bates, M. L. S., & Horrax, C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.017 · Cited by 42
Flanagan, J. C., Allan, N. P., Calhoun, C. D., Badour, C. L., Maria, M. M. M., Brady, K. T., & Back, S. E. (2018) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000232 · Cited by 43
Oxytocin prevents the increase of cocaine-related responses produced by social defeat
Perez, C. F., Castro‐Zavala, A., Luján, M. Á., Filarowska, J., Ballestín, R., Miñarro, J., Valverde, O., & Rodríguez‐Arias, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.011 · Cited by 40
The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review
Berardis, D. D., Marini, S., Iasevoli, F., Tomasetti, C., de Bartolomeis, A., Mazza, M., Valchera, A., Fornaro, M., Cavuto, M., Srinivasan, V., et al. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312020012 · Cited by 39
Bahí, A., Mansouri, S. A., & Maamari, E. A. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.06.009 · Cited by 38
Vaht, M., Kurrikoff, T., Laas, K., Veidebaum, T., & Harro, J. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.09.018 · Cited by 39
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34
Vasopressin and alcohol: a multifaceted relationship
Harper, K. M., Knapp, D. J., Criswell, H. E., & Breese, G. R. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5099-x · Cited by 35
Melby, K., Gråwe, R. W., Aamo, T. O., Salvesen, Ø., & Spigset, O. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.01.003 · Cited by 33
Lee, M. R., Schwandt, M. L., Sankar, V., Suchankova, P., Sun, H., & Leggio, L. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.07.481 · Cited by 33
Vena, A. A., Zandy, S. L., Cofresí, R. U., & Gonzales, R. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107573 · Cited by 33
Bardo, M. T., Hammerslag, L. R., & Malone, S. G. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108567 · Cited by 32
Impact of intranasal oxytocin on interoceptive accuracy in alcohol users: an attentional mechanism?
Betka, S., van Praag, C. G., Paloyelis, Y., Bond, R., Pfeifer, G., Sequeira, H., Duka, T., & Critchley, H. (2018) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsy027 · Cited by 32
Snider, B. M., Geiser, A., Yu, X.-P., Beebe, E., Willency, J. A., Qing, K., Guo, L., Lu, J., Wang, X., Yang, Q., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00004 · Cited by 32
Bach, P., Reinhard, I., Bühler, S., Vollstädt‐Klein, S., Kiefer, F., & Koopmann, A. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104385 · Cited by 29
Oxytocin and Addiction: Potential Glutamatergic Mechanisms
Sundar, M., Patel, D., Young, Z., & Leong, K.-C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052405 · Cited by 31
Oxytozin: Evidenz für ein therapeutisches Potenzial des sozialen Neuromodulators
Eckstein, M., & Hurlemann, R. (2013) · Der Nervenarzt · doi:10.1007/s00115-013-3832-6 · Cited by 28
Advances in Pharmacotherapy Development: Human Clinical Studies
Litten, R. Z., Falk, D. E., Ryan, M. L., Fertig, J. B., & Leggio, L. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_79 · Cited by 29
Oxytocin signaling in the treatment of drug addiction: Therapeutic opportunities and challenges
Che, X., Cai, J., Liu, Y., Xu, T., Yang, J., & Wu, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107820 · Cited by 28
Romantic Love vs. Drug Addiction May Inspire a New Treatment for Addiction
Zou, Z., Song, H., Zhang, Y., & Zhang, X. (2016) · Frontiers in Psychology · doi:10.3389/fpsyg.2016.01436 · Cited by 31
Bowen, M. T., & Neumann, I. D. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_17 · Cited by 28
Flanagan, J. C., Fischer, M. S., Nietert, P. J., Back, S. E., Maria, M. M.-S., Snead, A., & Brady, K. T. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2017.12.003 · Cited by 27
Factors contributing to the escalation of alcohol consumption
Bowen, M. T., George, O., Muskiewicz, D. E., & Hall, F. S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.017 · Cited by 29
Dunigan, A. I., & Roseberry, A. G. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100011 · Cited by 28
Mellentin, A. I., Finn, S. W., Skøt, L., Thaysen‐Petersen, D., Mistarz, N. T., Fink‐Jensen, A., & Nielsen, D. G. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105185 · Cited by 24
Giannotti, G., Mottarlini, F., Heinsbroek, J. A., Mandel, M. R., James, M. H., & Peters, J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02161-z · Cited by 25
Oxytocin modulates hemodynamic responses to monetary incentives in humans
Mickey, B. J., Heffernan, J., Heisel, C. J., Peciña, M., Hsu, D. T., Zubieta, J.-K., & Love, T. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4423-6 · Cited by 24
Stevenson, J. R., Young, K., Bohidar, A. E., Francomacaro, L. M., Fasold, T. R., Buirkle, J. M., Ndem‐Galbert, J. R., & Christian, S. C. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13430 · Cited by 25
Alcohol and oxytocin: Scrutinizing the relationship
Ryabinin, A. E., & Fulenwider, H. D. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.009 · Cited by 24
Can intranasal oxytocin reduce craving in automated addictive behaviours? A systematic review
Houghton, B., Kouimtsidis, C., Duka, T., Paloyelis, Y., & Bailey, A. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15617 · Cited by 26
Oxytocin treatment in pediatric populations
Taylor, A. E., Lee, H.-E., & Buisman‐Pijlman, F. T. A. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00360 · Cited by 23
Hicks, C., Ramos, L., Dampney, B., Baracz, S. J., McGregor, I. S., & Hunt, G. E. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.10.005 · Cited by 22
L’ocytocine et la dépression du post-partum
Cardaillac, C., Rua, C., Simon, E. G., & El‐Hage, W. (2016) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2016.05.002 · Cited by 23
Melby, K., Gråwe, R. W., Aamo, T. O., Skovlund, E., & Spigset, O. (2020) · Alcohol and Alcoholism · doi:10.1093/alcalc/agaa133 · Cited by 22
Systemic oxytocin administration alters mesolimbic dopamine release in mice
Estes, M. K., Freels, T. G., Prater, W. T., & Lester, D. B. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.04.006 · Cited by 25
Verplaetse, T. L. (2018) · Alcohol research · doi:10.35946/arcr.v39.2.09 · Cited by 22
Decreased Blood Levels of Oxytocin in Ketamine-Dependent Patients During Early Abstinence
Huang, M., Chen, L., Chang, H., Liang, X., Chen, C., Cheng, W., & Xu, K. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00633 · Cited by 21
Oxytocin treatment for alcoholism: Potential neurocircuitry targets
Peris, J., Steck, M. R., & Krause, E. G. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108091 · Cited by 21
King, C. E., Griffin, W. C., Lopez, M. F., & Becker, H. C. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01046-x · Cited by 21
Brust, J. C. M. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-62619-6.00008-2 · Cited by 21
Walcott, A. T., & Ryabinin, A. E. (2020) · Addiction Biology · doi:10.1111/adb.12893 · Cited by 21
Metadata
- Authors
- Pedersen, C. A., Smedley, K. L., Leserman, J., Jarskog, L. F., Rau, S. W., Kampov‐Polevoi, A., Casey, R. L., Fender, T., & Garbutt, J. C.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Pedersen, Cort A.
- Venue
- Alcoholism: Clinical and Experimental Research
- Publisher
- Wiley
- Published
- 2012-10
- Volume
- 37
- Issue
- 3
- Pages
- 484-489
- ISSN
- 0145-6008 (ISSN-L)
- 1530-0277
- PMC
- PMC3557665
- OpenAlex
- W2073015613
- Cited by
- 196
- References
- 51
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 8 · 2023: 8 · 2022: 16 · 2021: 16 · 2020: 16 · 2019: 12 · 2018: 23 · 2017: 28 · 2016: 23 · 2015: 9 · 2014: 12 · 2013: 9 · 2012: 2
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alcoholism Clinical and Experimental Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (5-P60-AA011605-08-13, P60AA011605)
- National Center for Research Resources (UL1RR025747)
- Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill
- Topics
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- oxytocin, intranasal administration, alcohol withdrawal, alcoholism, alcohol detoxification, alcohol craving, anxiety, mood states, benzodiazepine tolerance, neural adaptation
- MeSH terms
- Administration, Intranasal, Adult, Alcoholism, Double-Blind Method, Female, Humans, Male, Middle Aged, Oxytocin, Pilot Projects, Substance Withdrawal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
